RCT in 227 untreated patients with MDS with excess blasts (223 analysed): ATRA plus decitabine raised overall response vs decitabine alone (78% vs 51%; OR 3.40) and PFS (14.9 vs 10.5 months), with no significant OS difference.
RCTn = 227
Zhou et al. Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial